News

Ultragenyx's Angelman syndrome drug fails pivotal Phase 3 trial

Ultragenyx Pharmaceutical said on 2 September 2026 that its experimental drug for Angelman syndrome failed the main goal of a large late-stage trial, a setback that wiped roughly $1.1bn off the company's value and sent its shares down about 44% in after-hours trading.

Angelman syndrome is a rare genetic disorder, usually diagnosed in early childhood, that causes severe developmental delay, problems with movement and balance, seizures and little or no speech. It is caused by the loss of a working copy of a single gene, UBE3A , in the brain. Ultragenyx's drug, apazunersen (also known as GTX-102), was designed to switch back on a silenced back-up copy of that gene so the missing protein could be produced again.

In the Phase 3 Aspire study, apazunersen showed no meaningful benefit over a sham (placebo) treatment on the main measure of cognitive improvement, nor on the key secondary measure that combined gains across five areas such as communication and motor skills. Safety was in line with earlier studies. The result is a surprise because the drug had looked promising in earlier, smaller trials, raising hopes among families with few options. Ultragenyx said it will now review the programme's future and plans significant cost cuts while leaning on its existing approved products.

Source: Ultragenyx, 2 September 2026.

More top stories